Drug intelligence / Profile preview

SPH-102

Development stage: Preclinical
Lead developer: Sapphire Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

SPH-102 is an orally administered drug candidate being developed by Sapphire Therapeutics for the treatment of Crohn's Disease. It utilizes a non-immunosuppressive mechanism of action by targeting a novel, undisclosed receptor that modulates the NFkB and IL-22 signaling pathways. This approach is designed to provide therapeutic benefit in inflammatory bowel disease (IBD) by restoring intestinal homeostasis without the systemic immunosuppression common in current treatments like biologics or steroids. As of early 2024, SPH-102 is in the lead identification stage of preclinical development.

Beyond the preview

Go deeper on SPH-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPH-102.

Explore the full profile